Evidence map›Paper›PMID 28233466›Full record

ArticleAdvanced healthcare materials2017

Selectively Inducing Cancer Cell Death by Intracellular Enzyme-Instructed Self-Assembly (EISA) of Dipeptide Derivatives.

Jie Li, Junfeng Shi, Jamie E Medina, Jie Zhou, Xuewen Du, Huaimin Wang, Cuihong Yang, Jianfeng Liu, Zhimou Yang, Daniela M Dinulescu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced healthcare materials, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Static and Dynamic Biomaterial Engineering for Cell Modulation.Nanomaterials (Basel, Switzerland) · 2022
    Review
  10. Article
  11. Enzymatic Noncovalent Synthesis.Chemical reviews · 2020
    Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jie LiDepartment of Chemistry, Brandeis University, 415 South Street, Waltham, MA, 02454, USA.
Junfeng ShiDepartment of Chemistry, Brandeis University, 415 South Street, Waltham, MA, 02454, USA.
Jamie E MedinaDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Jie ZhouDepartment of Chemistry, Brandeis University, 415 South Street, Waltham, MA, 02454, USA.
Xuewen DuDepartment of Chemistry, Brandeis University, 415 South Street, Waltham, MA, 02454, USA.
Huaimin WangDepartment of Chemistry, Brandeis University, 415 South Street, Waltham, MA, 02454, USA.
Cuihong YangChinese Academy of Medical Science & Peking Union Medical College, Tianjin, 300192, China.
Jianfeng LiuChinese Academy of Medical Science & Peking Union Medical College, Tianjin, 300192, China.
Zhimou YangState Key Laboratory of Medicinal Chemical Biology and College of Life Sciences, Nankai University, Tianjin, 300071, China.
Daniela M DinulescuDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Bing XuDepartment of Chemistry, Brandeis University, 415 South Street, Waltham, MA, 02454, USA.

Funding

Subcellular Enzyme-instructed self-assembly for molecular anticancer nanomedicinesR01CA142746 · NCI · BRANDEIS UNIVERSITY · PI Bing Xu · 2010 to 2026
$6.4M
NCI NIH HHS R01 CA142746
6 · The paper itself

Abstract

Tight ligand-receptor binding, paradoxically, is a major root of drug resistance in cancer chemotherapy. To address this problem, instead of using conventional inhibitors or ligands, this paper focuses on the development of a novel process-enzyme-instructed self-assembly (EISA)-to kill cancer cells selectively. Here it is demonstrated that EISA as an intracellular process to generate nanofibrils of short peptides for selectively inhibiting cancer cell proliferation, including drug resistant ones. As the process that turns the non-self-assembling precursors into the self-assembling peptides upon the catalysis of carboxylesterases (CES), EISA occurs intracellularly to selectively inhibit a range of cancer cells that exhibit relatively high CES activities. More importantly, EISA inhibits drug resistant cancer cells (e.g., triple negative breast cancer cells (HCC1937) and platinum-resistant ovarian cells (SKOV3, A2780cis)). With the IC

Indexed as

Antineoplastic AgentsApoptosisCarboxylic Ester HydrolasesCell Line, TumorDipeptidesDose-Response Relationship, DrugHumansNeoplasms, ExperimentalTreatment OutcomeAntineoplastic AgentsCarboxylic Ester HydrolasesDipeptidesanticancerdrug-resistanceenzymeselectivityself-assembly

Identifiers

PMID28233466
PMCPMC5550337

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.